Clinical Trial

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

Study acronym: Solid Tumors
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-09
Trial Details
NCT Number NCT07639450
Lead Sponsor Hefei Xinzhu Biological Technology Co., Ltd.
Conditions Advanced Malignant Solid Tumors
Enrollment 114 participants
Start Date 2026-06-15
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-08